{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:00Z","timestamp":1786986960705,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2025.102498","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:11:44Z","timestamp":1767975104000},"page":"102498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Outcomes of Targeted Therapies Following HIF-2\u03b1 Inhibition in Metastatic Renal Cell Carcinoma: A Real-World Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-7418","authenticated-orcid":false,"given":"Patricia","family":"Rioja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Rey-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-016X","authenticated-orcid":false,"given":"Jorge","family":"Esteban-Villarrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Plata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Sparagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-9741","authenticated-orcid":false,"given":"Ray","family":"Manneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102498_bib0001","article-title":"Evolution of cell therapy for renal cell carcinoma","volume":"23","author":"Wang","year":"2024","journal-title":"Mole Cancer"},{"key":"10.1016\/j.clgc.2025.102498_bib0002","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00109-014-1180-z","article-title":"The role of HIF1\u03b1 in renal cell carcinoma tumorigenesis","volume":"92","author":"Gudas","year":"2014","journal-title":"J Mole Med"},{"key":"10.1016\/j.clgc.2025.102498_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102801","article-title":"Targeting HIF-2\u03b1 and anemia: a therapeutic breakthrough for clear-cell renal cell carcinoma","volume":"129","author":"Rioja","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2025.102498_bib0004","doi-asserted-by":"crossref","first-page":"oyae276","DOI":"10.1093\/oncolo\/oyae276","article-title":"Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma","volume":"30","author":"Choi","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2025.102498_bib0005","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/fon-2023-0679","article-title":"Belzutifan: a novel therapeutic for the management of von Hippel\u2013Lindau disease and beyond","volume":"20","author":"Curry","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2025.102498_bib0006","unstructured":"Motzer RJ, Memorial Sloan Kettering Cancer Center \u00de, Jonasch E, Agarwal N, et al. NCCN Guidelines Version 1.2026 Kidney Cancer Continue NCCN Guidelines Panel Disclosures. 2025 Accessed: August 21, 2025; Available at: https:\/\/www.nccn.org\/home\/."},{"issue":"8","key":"10.1016\/j.clgc.2025.102498_bib0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.clgc.2025.102498_bib0008","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102498_bib0009","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102498_bib0010","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3390\/diagnostics13142430","article-title":"Second-line treatment of metastatic renal cell carcinoma in the era of predictive biomarkers","volume":"13","author":"Parosanu","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.clgc.2025.102498_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/KCA-230024","article-title":"Belzutifan versus everolimus in advanced kidney cancer: a commentary on LITESPARK-005 trial from ESMO 2023","volume":"8","author":"Gulati","year":"2024","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.clgc.2025.102498_bib0012","first-page":"190","article-title":"Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study","volume":"27","author":"Doma\u0144ski","year":"2023","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.clgc.2025.102498_bib0013","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00280-015-2725-8","article-title":"Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor","volume":"75","author":"Park","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102498_bib0014","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102498_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102498_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-019-0752-z","article-title":"HIF inhibitors: status of current clinical development","volume":"21","author":"Fallah","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.clgc.2025.102498_bib0017","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(25)00032-4","article-title":"Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial","volume":"26","author":"Powles","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102498_bib0018","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(18)30648-X","article-title":"Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study","volume":"19","author":"Voss","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102498_bib0019","doi-asserted-by":"crossref","first-page":"101335","DOI":"10.1016\/j.mam.2024.101335","article-title":"The molecular code of kidney cancer: a path of discovery for gene mutation and precision therapy","volume":"101","author":"Xie","year":"2025","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.clgc.2025.102498_bib0020","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102498_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1035321","article-title":"PIMREG is a prognostic biomarker involved in immune microenvironment of clear cell renal cell carcinoma and associated with the transition from G1 phase to S phase","volume":"13","author":"Yao","year":"2023","journal-title":"Front Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:29:48Z","timestamp":1771705788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1558767325001983"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102498","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Targeted Therapies Following HIF-2\u03b1 Inhibition in Metastatic Renal Cell Carcinoma: A Real-World Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102498"}}